Overweight, Obesity, Type 2 Diabetes research hub

J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)

This study is looking at a new daily tablet (called ORFORGLIPRON) for adults who are overweight or have obesity and also have type 2 diabetes. It aims to see how well it helps with weight loss and if it's safe compared to a dummy pill.